295 related articles for article (PubMed ID: 19546825)
1. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
[TBL] [Abstract][Full Text] [Related]
2. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA;
Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271
[TBL] [Abstract][Full Text] [Related]
4. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
[TBL] [Abstract][Full Text] [Related]
5. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
6. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women.
Ronkin S; Northington R; Baracat E; Nunes MG; Archer DF; Constantine G; Pickar JH
Obstet Gynecol; 2005 Jun; 105(6):1397-404. PubMed ID: 15932835
[TBL] [Abstract][Full Text] [Related]
7. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
8. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.
Christiansen C; Chesnut CH; Adachi JD; Brown JP; Fernandes CE; Kung AW; Palacios S; Levine AB; Chines AA; Constantine GD
BMC Musculoskelet Disord; 2010 Jun; 11():130. PubMed ID: 20569451
[TBL] [Abstract][Full Text] [Related]
9. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.
Harvey JA; Holm MK; Ranganath R; Guse PA; Trott EA; Helzner E
Menopause; 2009; 16(6):1193-6. PubMed ID: 19503006
[TBL] [Abstract][Full Text] [Related]
10. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
11. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Palacios S
Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
[TBL] [Abstract][Full Text] [Related]
13. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.
de Villiers TJ; Chines AA; Palacios S; Lips P; Sawicki AZ; Levine AB; Codreanu C; Kelepouris N; Brown JP
Osteoporos Int; 2011 Feb; 22(2):567-76. PubMed ID: 20535606
[TBL] [Abstract][Full Text] [Related]
15. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
Palacios S; Silverman SL; de Villiers TJ; Levine AB; Goemaere S; Brown JP; De Cicco Nardone F; Williams R; Hines TL; Mirkin S; Chines AA;
Menopause; 2015 Aug; 22(8):806-13. PubMed ID: 25668306
[TBL] [Abstract][Full Text] [Related]
16. Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes.
Goldstein SR; Neven P; Cummings S; Colgan T; Runowicz CD; Krpan D; Proulx J; Johnson M; Thompson D; Thompson J; Sriram U
Menopause; 2011 Jan; 18(1):17-22. PubMed ID: 20689465
[TBL] [Abstract][Full Text] [Related]
17. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis.
Genant HK
Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498
[TBL] [Abstract][Full Text] [Related]
18. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
[TBL] [Abstract][Full Text] [Related]
20. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.
de Villiers TJ
Climacteric; 2010 Jun; 13(3):210-8. PubMed ID: 20184423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
